The specter of generic challenges has repeatedly loomed above copyright’s iconic drug, Sildenafil, triggering questions about the prospects of related pharmaceutical portfolios. While early times saw significant returns, the patent end has allowed the way for discounted substitutes, likely reducing profitability and presenting a genuine hazard fo